Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 3
1992 2
1993 5
1994 4
1995 3
1996 6
1997 7
1998 1
1999 6
2000 4
2001 3
2002 3
2003 5
2004 1
2005 5
2006 2
2007 3
2008 1
2010 5
2013 1
2015 2
2016 1
2017 11
2018 2
2019 2
2020 10
2021 6
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

105 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. Among authors: gantz i. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714 Clinical Trial.
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK; VERTIS CV Investigators. Cosentino F, et al. Among authors: gantz i. Circulation. 2020 Dec 8;142(23):2205-2215. doi: 10.1161/CIRCULATIONAHA.120.050255. Epub 2020 Oct 7. Circulation. 2020. PMID: 33026243 Free PMC article. Clinical Trial.
The melanocortin system.
Gantz I, Fong TM. Gantz I, et al. Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E468-74. doi: 10.1152/ajpendo.00434.2002. Am J Physiol Endocrinol Metab. 2003. PMID: 12556347 Free article. Review.
Novel insights into histamine H2 receptor biology.
Del Valle J, Gantz I. Del Valle J, et al. Among authors: gantz i. Am J Physiol. 1997 Nov;273(5):G987-96. doi: 10.1152/ajpgi.1997.273.5.G987. Am J Physiol. 1997. PMID: 9374694 Review.
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.
Kadowaki T, Seino Y, Kaku K, Okamoto T, Kameya M, Sato A, Hirano T, Oshima N, Gantz I, O'Neill EA, Engel SS; Omarigliptin Study 039 Group. Kadowaki T, et al. Among authors: gantz i. Diabetes Obes Metab. 2021 Jun;23(6):1242-1251. doi: 10.1111/dom.14331. Epub 2021 Feb 17. Diabetes Obes Metab. 2021. PMID: 33512755 Free PMC article. Clinical Trial.
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
Dagogo-Jack S, Pratley RE, Cherney DZI, McGuire DK, Cosentino F, Shih WJ, Liu J, Frederich R, Mancuso JP, Raji A, Gantz I. Dagogo-Jack S, et al. Among authors: gantz i. BMJ Open Diabetes Res Care. 2021 Oct;9(1):e002484. doi: 10.1136/bmjdrc-2021-002484. BMJ Open Diabetes Res Care. 2021. PMID: 34620621 Free PMC article. Clinical Trial.
105 results